A recent genome-wide association study (GWAS) conducted by the International Multiple Sclerosis Genetics Consortium (IMSGC) identified a number of putative MS susceptibility genes. Here we have performed a replication study in 1134 Australian MS cases and 1265 controls for 17 risk-associated single nucleotide polymorphisms (SNPs) reported by the IMSGC. Of 16 SNPs that passed quality control filters, four, each corresponding to a different non-human leukocyte antigen (HLA) gene, were associated with disease susceptibility: KIAA0350 (rs6498169) P ¼ 0.001, IL2RA (rs2104286) P ¼ 0.033, RPL5 (rs6604026) P ¼ 0.041 and CD58 (rs12044852) P ¼ 0.042. There was no association (P ¼ 0.58) between rs6897932 in the IL7R gene and the risk of MS. No interactions were detected between the replicated IMSGC SNPs and HLA-DRB1*15, gender, disease course, disease progression or age-at-onset. We used a novel Bayesian approach to estimate the extent to which our data increased or decreased evidence for association with the six most-associated IMSGC loci. These analyses indicated that even modest P-values, such as those reported here, can contribute markedly to the posterior probability of 'true' association in replication studies. In conclusion, these data provide support for the involvement of four non-HLA genes in the pathogenesis of MS, and combined with previous data, increase to genome-wide significance (P ¼ 3 Â 10
Introduction
Multiple sclerosis (MS) is the most common demyelinating disease, affecting around 1 in 1000 individuals of North European ancestry. MS is 2-3 times more common in females than males, and siblings of affected individuals are around 20 times more likely to have MS (l s ¼ 20) than unrelated individuals.
Like other genetically complex diseases with an autoimmune etiology, such as Type I diabetes mellitus (T1D) and rheumatoid arthritis, variation in the human leukocyte antigen (HLA) complex is associated with susceptibility to MS. In MS, the class II haplotype, DRB1*1501-DQB1*0602, is strongly associated with disease susceptibility, but there is now convincing evidence of complexity and allelic heterogeneity at this locus, 1, 2 and evidence for an alternate susceptibility locus in the class I region. 3 Only recently have large genetic studies provided strong statistical and functional evidence for the involvement of non-HLA genetic variation in disease pathogenesis.
With the advent of dense single nucleotide polymorphism (SNP) maps of the human genome, the HapMap Project 4 and arrays that permit high-throughput SNP genotyping, well-powered genome-wide association studies (GWAS) have become logistically and financially feasible. Recently the International MS Genetics Consortium (IMSGC) published the first SNP-based GWAS for MS with the aim of identifying novel MS susceptibility genes, and a list of 17 SNPs in 13 different gene loci were reported as showing statistical evidence (P ¼ 6 Â 10 À3 to P ¼ 9 Â 10
À81
) of association with disease susceptibility. 5 Replication studies have since been performed, and provide support for a causal link between variation in the interleukin 7 receptor (IL7R), [6] [7] [8] interleukin 2 receptor alpha (IL2RA, also known as CD25), [8] [9] [10] EV15 11 and disease pathogenesis.
In this study, our aim was to validate the associations observed between all 17 IMSGC SNPs and disease susceptibility in a collection of Australian MS cases and controls. We provide additional evidence for the involvement of IL2RA, and three other non-HLA genes, KIAA0350, RPL5 and CD58, in the pathogenesis of MS.
Results
In 1146 Australian MS cases and 1309 healthy controls 17 MS-associated SNPs were genotyped. One SNP in the EV15 (rs6680578) gene displayed a significant (Po0.001) departure from Hardy-Weinberg equilibrium in controls. Of the 2455 DNA samples genotyped, 56 (12 MS cases and 44 controls (2.3%)) had less than 50% of available genotypes and were removed. Therefore, the effective sample size for this study was 1134 MS cases and 1265 controls.
Association between SNPs in four non-HLA genes and risk of MS As expected, the most associated SNP was rs3135388 (rs3135388; P ¼ 1 Â 10
À33
, allelic odds ratio (OR) 2.49; 95% confidence interval, (2.15-2.89)), which is strongly correlated with the HLA-DRB1*1501 allele in our sample (data not shown) ( Table 1 ). The most associated non-HLA gene (ranked third by the IMSGC behind IL2RA and IL7R) was KIAA0350 (P ¼ 0.001; OR 1.23 (1.09-1.39)). Pooling our data for the KIAA0350 SNP (rs6498169) with that of the IMSGC 5 increased to genome-wide significance (P ¼ 3 Â 10
À8
; OR 1.16 (1.10-1.22)) the evidence of association of this gene with MS susceptibility. The function of KIAA0350 (also known as CLEC16A) is unknown, and it is expressed in cells of both immune and neurological origin. The associated G allele of rs6498169 is located in the same intron (21) and haplotype block as two SNPs (rs2903692, rs17673553) that are significantly associated with susceptibility to T1D, 12 however, neither are in strong linkage disequilibrium (LD) with rs6498169 in HapMap (CEU, Caucasian European) samples of North European origin (r 2 ¼ 0.187 for rs2903692, and r 2 ¼ 0.261 for rs17673553). The most associated T1D-associated SNP (rs12708716) identified by Todd et al. 13 is located some 69.46 kb telomeric of rs6498169 in intron 18 of KIAA0350 and is also in weak LD (r 2 ¼ 0.259) with rs6498169 in HapMap samples. It is noteworthy that rs12708716 is in strong pair-wise LD with both rs2903692 (r 2 ¼ 0.958) and rs17673553 (r 2 ¼ 0.657). A SNP (rs2104286) in the first intron of the IL2RA gene on chromosome 10p15 was associated with predisposition to MS in our sample (P ¼ 0.033; OR 1.16 (1.01-1.33)). IL2RA (also known as CD25) is expressed on the surface of activated T-cells and regulatory T-cells, and is also implicated in the susceptibility to T1D.
14 In T1D, the causal variant(s) appears to be associated with lower levels of soluble IL2RA, raising the possibility that a lower immune responsiveness may be predisposing. 15 We found that a second IMSGC SNP (rs12722489), which is in LD with rs2104286 in both HapMap (r 2 ¼ 0.62) and Australian samples (r 2 ¼ 0.49), was not significantly associated with risk in our study (P ¼ 0.156). Although rs12722489 was significantly associated with risk in a recent validation study conducted in over 600 Canadian MS families, 10 it showed only marginal association (P ¼ 0.065) with risk in a combined French and German sample. 8 We did not genotype rs1570538, which was associated with risk in Spanish MS patients. 9 Located in intron 6 of the RPL5 (ribosomal protein L5) gene on chromosome 1p22, rs6604026 was associated with the risk of MS (P ¼ 0. Finally, we found evidence of a predisposing effect for rs12044852 (P ¼ 0.042; OR 1.2 (1.01-1.44)), which is located in intron 1 of the CD58 gene (also known as lymphocyte function-associated antigen-3).
Genotype-phenotype correlations
Logistic regression was performed to determine whether any of the four associated non-HLA SNPs (rs6498169 (KIAA0350), rs2104286 (IL2RA), rs6604026 (RPL5) and rs12044852 (CD58)) displayed evidence of interaction with each other, the HLA-DRB1*1501 allele, gender, clinical course, multiple sclerosis severity score 16 or age-at-onset of MS. No significant interactions or associations were observed (data not shown).
Estimation of posterior probabilities of 'true' association
In order to estimate the contribution of our results to existing data we calculated the posterior probability of association (probability of the association being 'true') for each of the seven most-associated SNPs in the six most-associated gene loci in the IMSGC study (IL2RA, IL7R, KIAA0350, RPL5, DBC1 and CD58) ( Table 1) . Approximate Bayes factors (ABF) were calculated for each of the SNPs (refer to Supplementary data); where an ABF o1 implies increased evidence for association, and an ABF 41 implies reduced evidence for association (Table 2) . These ABFs were then used to convert a range of arbitrarily chosen prior probabilities of association (0.99, 0.95, 0.9, 0.7, 0.5 and 0.3) into posterior probabilities of association. An increase in the posterior probability of association over and above the prior probability indicates the extent to which our data increases evidence for that SNP being a 'true' association. Accordingly, a reduction below the prior probability implies that our data decreases evidence that the corresponding SNP is truly associated with susceptibility to MS. It should be noted that the exact prior probability cannot be known for any locus, which is why we have investigated the contribution of our data with respect to a range of plausible prior probabilities.
The most associated non-HLA SNP, rs6498169, in the KIAA0350 gene had an ABF of 0.008. This means that, for example, if the prior probability of this association were 0.5 before our data were available (that is, an evens, or 1:1, chance), the posterior probability of this association being 'true' now would be 0.992 (or odds of about 100:1 in favor), where the odds of association equal probability of association/(1Àprobability of association). Interestingly we found that, for other SNPs showing suggestive evidence of association with risk (rs2104286, rs6604026, rs12044852), posterior probabilities of 'true' association were substantially higher than prior Power calculations for the effective sample of 1134 AUS case and 1265 controls were calculated using the Genetic Power Calculator. 26 Percentage power to detect association at the P ¼ 0.05 significance level are listed assuming the risk allele OR reported for the IMSGC GWAS (931 MS trio families) and combined IMSGC samples (1540 MS trio families, 2322 MS cases, and 5418 controls), respectively. The disease frequency was estimated at 0.001 (1:1000) and the marker and disease allele were assumed to be of equivalent frequency and in complete (D 0 ¼ 1) linkage disequilibrium (LD). A multiplicative model was assumed for the effect of each putative risk allele. Logistic regression was used to perform allelic tests of association and to estimate ORs and 95% CIs. The EV15 SNP, rs6680578, is shaded because it was significantly deviated (Po0.001) from the Hardy-Weinberg equilibrium in controls, and is included in this table because the association between EV15 and MS was recently replicated elsewhere. probabilities. Posterior probabilities were also marginally higher than prior probabilities for rs12722489 (IL2RA), which did not reach our Pp0.05 significance threshold. It is also worth noting that our failure to replicate the association with IL7R may not substantially diminish the evidence for association given the strong prior probability (perhaps 0.99) of association. Please refer to the Supplementary data for a more detailed description of this analysis.
Discussion
None of the 16 non-HLA SNPs identified by the IMSGC in their genome-wide scan were significantly associated with risk of MS at genome-wide significance (Po5 Â 10
À7
). 5 Nevertheless, P-values for the six most associated non-HLA genes (IL2RA, IL7R, KIAA0350, RPL5, DBC1 and CD58) decreased by around 2-5 orders of magnitude with further genotyping in a larger combined sample, and both IL2RA and IL7R passed this threshold subsequently. Here we report that the KIAA0350 gene also passes the threshold for genomewide significant evidence of association with disease susceptibility when our data is combined with that of the IMSGC.
The variants tested in this study were selected because of their a priori association with risk of MS, but none of the SNPs meeting our threshold of significance for replication (Pp0.05) would be considered alone as providing any more than suggestive evidence of association. Indeed, only the association with KIAA0350 would be regarded as significant after correction for 16 tests. Thus, to estimate the contribution of our data to existing evidence we asked the question: how much more or less likely are these associations to be 'true' now after the addition of our data? For SNPs in the six most-associated non-HLA genes from the IMSGC study, we estimated ABF and calculated the posterior probabilities of 'true' association under a range of prior probability scenarios. Although one needs to remain circumspect about conclusions drawn from these data because the prior probability of association cannot be known, this analysis shows that SNPs only modestly associated with risk can make a fairly substantial contribution to the overall evidence for 'true' association.
We replicated associations for four of the six top IMSGC candidate genes despite having modest-low power (75-27%) in this study. A notable exclusion from the list of replicated loci was IL7R, and given the existing prior evidence for its involvement in susceptibility to MS [6] [7] [8] 10 it would be reasonable to expect that this locus should be amongst those replicated. It is comforting that allele frequencies for all the SNPs tested here were very similar to those reported by the IMSGC and other groups, however, it remains interesting that the reported rs6897932C IL7R risk allele is actually less frequent in Australian MS cases (0.751) than controls (0.758). To determine whether population stratification might have influenced allele frequencies in this study, we reanalysed the data only for 916 cases reporting North European ancestry for both parents (refer to methods), bearing in mind that all controls were ascertained on that basis. However, the OR, which decreased from 0.96 to 0.91, still did not provide evidence of a predisposing effect of rs6897932C in our sample. Reasons for this discrepancy might include (a) random sampling variation (b) subtle population-specific environmental influences, which may render rs6897932C more or less 'potent,' or (c) systematic differences in sample preparation, SNP assay design and/or performance, which may have affected genotype calling, and thus the propensity for differential effects on allele frequencies. Alternatively, rs6897932 might simply not be associated with risk of MS in Australians.
We have replicated associations for four non-HLA MS candidate genes identified recently by the IMSGC. Variation in two of these loci, IL2RA and KIAA0350, is also associated with risk of T1D, providing further evidence of a pathophysiological link between these common inflammatory diseases. Fine scale mapping, followed by deep re-sequencing and functional studies will be required to identify the causal variations underlying these associations.
Materials and methods

Study subjects
From the southeastern Australian States of Victoria (n ¼ 986) and Tasmania (n ¼ 160), a total of 1146 MS cases were recruited. Most of the Tasmanian MS patients An approximate Bayes factor (ABF) was calculated for each SNP, where an ABFo1 indicates increased evidence for a 'true' association and an ABF41 indicates decreased evidence. Arbitrarily selected prior probabilities (0.99-0.3) of true association are indicated in bold type for the seven most associated non-HLA SNPs from the IMSGC study. Posterior probabilities of 'true' association are indicated in italics for each prior probability, after data from the current study.
have been studied previously in mapping studies of the HLA complex, 17-19 and a subset of the Victorian MS patients were included in a prevalence study of the hemochromatosis mutation, HFE-C282Y, alongside the Tasmanian sample. 20 A combined total of 1309 healthy controls were ascertained from the Melbourne (Victoria) node of the Australian Bone Marrow Donor Registry (n ¼ 1214), which recruits donors from both Victoria and Tasmania, and through the Menzies Research Institute in Tasmania (n ¼ 95). We estimate that this study involves 20-30% of all MS cases residing in Victoria and Tasmania.
Tasmanian MS cases and controls, and Victorian MS cases involved in this study were recruited under ethical approval from the Southern Tasmanian Human Research Ethics Committee (University of Tasmania) and The Melbourne Health Human Research Ethics Committee (Royal Melbourne Hospital), respectively. The Australian Bone Marrow Donor Registry Ethics Committee approved the use of genomic DNA samples from deidentified donors. The Australian Bone Marrow Donor Registry controls used in this study were of North European Caucasian ancestry. Of the Tasmanian MS cases and controls, all subjects reported either Australian, British or North European ancestry. For the Victorian MS cases; 756 (76.7%) reported having both parents born in either Australia, or a North European country, 140 (14.2%) reported that both parents were born in either southern or central European countries, and a further 40 (4.1%) cases were of mixed European ancestry. The remaining 5% of the subjects reported either Middle Eastern, Asian or African ancestry, or this was unknown due to adoption.
Phenotypic assessments of MS patients were conducted by; (T Kilpatrick, H Butzkueven, B Taylor, N Tubridy, M Marriott, C Chapman) according to established clinical 21, 22 and para-clinical 23 criteria. All patients had either (a) definite MS (b) clinically definite MS (c) laboratory-supported definite MS according to the McDonald and Poser criteria, respectively. Table 3 contains demographic information for MS patients involved in this study.
Genotyping
Genomic DNA was extracted from whole blood for MS cases and controls according to standard protocols, and was stored in 1 Â TE buffer. DNA concentrations were measured on a Nanodrop ND-1000 (Thermo Fisher Scientific, Wilmington, DE, USA) spectrophotometer and aliquots of 500 ng were adjusted to 5-10 ng/ml in water, arrayed into 96-well plates, and sent frozen to the Broad Institute Center for Genotyping and Analysis (http://www.broad.mit.edu/gen_analysis/genotyping/). Sequenom's MassARRAY platform (San Diego, CA, USA) was used for genotyping of all 17 IMSGC SNPs using the iPlex SNP assay design system.
HLA typing HLA-DRB1 typing was performed using sequencespecific oligonucleotide hybridization 24 and sequence based typing, 25 and was available for 93.9%. (n ¼ 1076) of all 1146 MS cases and 99.4% of (n ¼ 1301) all 1309 controls at two or four digit resolution. All HLA-DR2 carriers were genotyped to four-digit resolution. Of the HLA typed cases and controls, 56.3% (n ¼ 606) and 29.7% (n ¼ 386) were carriers of at least one copy of the HLA-DRB1*1501 allele, respectively. and between pairs of SNPs and disease susceptibility, and to test for association between SNPs and disease subtype (primary progressive compared with relapsing-remitting and secondary progressive disease, combined). Linear regression was used to test for association with age-at-onset and global multiple sclerosis severity score. 16 Logistic regression was used to model counts of alleles, with study (IMSGC or Australian) included as a covariate, to determine whether our results increased to genome-wide significance the evidence for association of the KIAA0350 SNP (rs6498169) with risk of MS. A 2 Â 2 case-control contingency table was constructed to approximate the IMSGC study 'combined' results, by counting each MS trio family as one case and one control and choosing allele counts to match the published allele frequency (0.37), OR (1.14) and P-value (3.83 Â 10
À6
). 5 To determine whether the replication dataset was increasing or reducing the evidence of association for various SNPs, ABFs were calculated using a method similar to that proposed recently 28 (refer to Supplementary data).
Genomic coordinates used in this study were derived from the March 2006 human reference sequence (NCBI Build 36.1) at the University California Santa Cruz (UCSC) Website (http://www.genome.ucsc.edu). Phase II HapMap data (January 2007, NCB1 Build 35) was derived from the website of the International HapMap Project (http://www.hapmap.org).
